Physician

Akwasi Afriyie Boateng, M.D.

According to 2025 Medicare claims, Akwasi Boateng, M.D. (NPI: 1144541996) practices urology in the Lakewood-New Brunswick, NJ market, with the plurality of this provider's patient population coming from Middlesex, NJ. This provider's primary affiliated billing organization is SUMMIT MEDICAL GROUP PA (NPI: 1942254347; TIN: 223487984) and primary practice location at 08816-5426. Boateng is affiliated with the Summit Health ACO (ACO ID: A5049), participating under the MSSP model.

Boateng's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 655 traditional Medicare patients, billed 8,591 HCPCS/CPT codes, and received $286,554 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,419 prescription claims across 621 beneficiaries totaling $657,606 in drug costs, led by Erleada (Apalutamide). 2023 DME data shows 63 claims. Open Payments data shows 1 records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $4,114 to $286,554. Similarly, Part D prescription costs have risen steadily, from $2,506 to $657,606. In contrast, DME billing represents a smaller volume and moved sharply higher in recent years, from $171 to $1,081.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	23	44	$4,114
2016	371	1,513	$120,250
2017	470	2,022	$147,751
2018	513	3,052	$214,301
2019	527	6,685	$256,109
2020	461	7,221	$358,026
2021	535	7,375	$485,658
2022	591	7,846	$287,219
2023	714	7,626	$278,330
2024	655	8,591	$286,554

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	46	107	$2,506
2016	113	353	$20,804
2017	206	660	$35,757
2018	276	1,009	$166,486
2019	337	1,330	$628,387
2020	327	1,427	$534,724
2021	361	1,463	$408,840
2022	465	1,834	$455,881
2023	580	2,271	$602,826
2024	621	2,419	$657,606

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	13	$1,514
2019	N/R	27	$497
2020	N/R	72	$1,819
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	63	$7,704
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	368	602	$101
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	366	534	$70
76857	Limited ultrasound scan of pelvis	307	453	$39
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	148	166	$14
81003	Automated urinalysis test	180	233	$2

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Erleada	Apalutamide	17	510	$243,875
Myrbetriq	Mirabegron	243	13,334	$197,159
Abiraterone Acetate	Abiraterone Acetate	26	780	$121,899
Gemtesa	Vibegron	37	2,050	$33,198
Methenamine Hippurate	Methenamine Hippurate	97	6,105	$9,221

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	0	$0	N/R
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	1	$25,000	Valencia Technologies Corporation

Explore More Providers

FAQ

What Medicare data is available for Akwasi Afriyie Boateng, M.D.?

Tedicare shows public-source Medicare data for Akwasi Afriyie Boateng, M.D. (NPI 1144541996), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Akwasi Afriyie Boateng, M.D. have ACO affiliation data?

Akwasi Afriyie Boateng, M.D. is shown with ACO affiliation data for Summit Health ACO (MSSP, ACO ID A5049).

What billing organization is linked to Akwasi Afriyie Boateng, M.D.?

Akwasi Afriyie Boateng, M.D. is linked to SUMMIT MEDICAL GROUP PA (billing NPI 1942254347) in the available physician profile data.

Does Akwasi Afriyie Boateng, M.D. have Open Payments data?

Akwasi Afriyie Boateng, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.